Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07002320 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Study acronym: ASpiRE
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 1 of 4 sitesv5
  2. Site details revised at 1 of 4 sitesv4
  3. Site details revised at 1 of 4 sitesv3
  4. Secondary endpoints revised (11)
    • Study title shortened, about 1 word
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).
Trial Details
NCT Number NCT07002320
Lead Sponsor Institute of Cancer Research, United Kingdom
Collaborators: Prostate Cancer UK, Janssen Pharmaceutica N.V., Belgium, Oncology Institute of Southern Switzerland, Syntrix Biosystems, Inc., Royal Marsden NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Belfast Health and Social Care Trust, Institute of Oncology Research (IOR)
Conditions
(from sponsor)		 Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Related terms Prostatic Neoplasms
Enrollment 78 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov